Assessment of Needs
With the ongoing demands of responding to the COVID-19 pandemic, clinicians and other frontline health care professionals are particularly vulnerable to burnout, stress, and other negative mental health effects. In this panel webinar, the IAS–USA Board of Directors will share personal stories of their experiences from early on during the pandemic to now, including how they have been dealing with the surge of COVID-19 cases and coping with stress. The panel will be moderated by Nadine J. Kaslow, PhD, Professor of Psychiatry and Behavioral Sciences at Emory University.
On completion of this webinar, learners will be able to:
- Describe approaches that thought leaders in the field have used to manage stress and maintain mental and overall health and use those strategies to keep up their own health and the health of staff and colleagues
- Describe the magnitude of the response to the COVID-19 pandemic and its effects upon everyone in the health care system
Who Should Attend
This webinar is designed for clinical decision makers who are actively involved in HIV care and research.
This activity is also relevant for registered nurses, pharmacists, and other health professionals.
Individual registration is required, even if you are viewing as a group, in order to receive continuing education credit or a certificate of participation.
Registration closes on Tuesday, February 23, 12:00 PM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at firstname.lastname@example.org.
Conflicts of Interest
In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.
The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Panelists and Moderator Disclosures
Dr Benson has served on advisory and data safety monitoring boards for GlaxoSmithKline/ViiV Healthcare, received research grants awarded to her institution from Gilead Sciences, Inc., and serves as a consultant to NDA Partners, LLC. Her spouse has served as a consultant to CytoDyn, AbbVie and Sempra Energy; owns stock options in Antiva Biosciences and CytoDyn; has served on the board for Gilead Sciences, Inc., with payment remitted to his institution; and has served on data and safety monitoring boards for Gilead Sciences, Inc., and VIR. (Updated 07/27/20)
Dr Currier has served on the advisory board for Merck & Co, Inc. (Updated 05/15/19)
Dr del Rio has no relevant financial affiliations to disclose. (Updated 06/20/20)
Dr Gulick has no relevant financial affiliations to disclose. (Updated 09/10/20)
Dr Kaslow has no relevant financial affiliations to disclose. (Updated 02/11/21)
Dr Marrazzo has received research grants from Merck & Co, Inc, and Cepheid; served as an advisor to Gilead Sciences, Inc, and BioFire Diagnostics, and served on a data safety monitoring board for Gilead Sciences, Inc. (Updated 09/02/19)
Dr Richman has been a consultant to Antiva Biosciences, Gilead Sciences, Inc, and Viriome, Inc. (Updated 12/10/20)
Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc, and ViiV Healthcare. (Updated 06/20/20)
Dr Schooley has served as a consultant to CytoDyn and has receives royalties from Antiva Biosciences and CytoDyn. He serves on the board for Gilead Sciences, Inc., with payment remitted to his institution. He serves on the data and safety monitoring boards for Gilead Sciences, Inc., and VIR with payment remitted to his institution. (Updated 02/20/20)
Dr Volberding has served on data and safety monitoring boards for Merck & Co, Inc. (Updated 06/20/20)
All relevant financial relationships have been mitigated.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.25 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.25 contact hours (0.125 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-21-039-L01-P
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc
Merck & Co, Inc
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at email@example.com or 415-544-9400.